## Imaging characterization of a metastatic patient derived model of adenocarcinoma pancreas: (PDMR-521955-158-R4)

### Summary

#### **Redirection Notice**

This page will redirect to https://www.cancerimagingarchive.net/collection/pdmr-521955-158-r4/ in about 5 seconds.

Pre-clinical animal models of spontaneous metastatic cancer are infrequent; the few that exist are resource intensive because determination of the presence of metastatic disease, metastatic burden, and response to therapy normally require multiple timed cohorts with animal sacrifice and extensive pathological examination. We identified and characterized a patient derived xenograft model with metastatic potential, adenocarcinoma pancreas xenograft 521955-158-R4. In this study we performed a detailed imaging characterization (workflow below) of this model, which develops spontaneous lung metastases, details are provided in the attached standard operating procedures. Tumors in half of the mice were resected in the range 200-300 mm<sup>3</sup> size; tumors in the other half were allowed to grow until it was necessary to euthanize them because of tumor size.

# PDX Tumor Development Tumor Fragment (repository) Tissue Implant (n=5) (Donors: ≤ P3) Tissue Implant (n=20) (Study mice: ≤ P3 +1) Tissue Implant (n=20) (Study mice: ≤ P3 +1) Characterize primary tumor MRI, PET/CT (FDG and FLT). Other imaging techniques can be included if indicated. Pathological confirmation of human tissue No observed (MRI)? Statistical Results (# mice w/o metastasis) No ohort with tumor fragments No observed (MRI)? Resected (n=10) Bi weekly MRI End monitoring when tumor regrowth (resected cohort) at ACUC limit; or max # MRI biweekly sessions attained. End monitoring for mets.

Workflow: Characterization of PDX primary tumor and metastasis

The imaging characteristics of this model (PDMR-521955-158-R4), which is available from the National Cancer Institute Patient-Derived Models Repository (https://pdmr.cancer.gov/), is highly favorable for preclinical research studies of metastatic disease when used in conjunction with non-contrast T2 weighted MRI.

#### Results: Adenocarcinoma pancreas (PDMR-521955-158-R4)

Table 1: Penetrance and location of pathological confirmed metastatic lesion(s).

	# animals that displayed metastasis in MRI and confirmed by Pathology	Pathology confirmation of MRI (primary imaging site)	Other confirmed Location (s)	Mouse ID: MRI with pathology confirmation of metastasis
--	---	--	------------------------------------	---

	4	Lung	Lung	2163, 2169, 2171, 2179
10 (non-resected)	(5 mice were EU due to xenograft size prior to observation of metastases)			
10 (resecte d)	7	Lung	Lung (70%) Paravertebral muscle (50%) Nodal disease (10%)	2160, 2161, 2164, 2170, 2172, 2176, 2178

Percent penetrance with respect to the average time-to-metastasis for non-resected (time from implant:  $10.7 \pm 1.8$  weeks) and resected (time from tumor resection:  $5.3 \pm 1.1$  weeks) cohorts.

PET/CT Characterization of the primary tumor: Baseline PET (SOP attached) were performed when tumor reached an approximate 200 mm<sup>3</sup>. Average SUVmax values (n=6) were calculated; [ $^{18}$ F]FDG: 2.3 ± 0.8 and [ $^{18}$ F]FLT: 2.4 ± 0.4.

#### Conclusion:

Good metastatic model with 40% penetrance un-resected and 70% with planned early resection. Metastases are well observed on T2 MRI imaging allowing non-invasive evaluation in treatment trials.

#### Acknowledgements

We would like to acknowledge the individuals and institutions that have provided data for this collection:

- Frederick National Laboratory for Cancer Research Special Thanks to Joseph D. Kalen, PhD, Lilia V. Ileva, MS, Lisa A Riffle, Nimit L Patel, MS, Keita Saito, PhD, Yvonne Evrard, PhD, Elijah Edmondson, DVM, PhD, Justin Smith, Simone Difilippantonio, PhD, Chelsea Sanders, Ulrike Wagner, Yanling Liu, PhD, John B. Freymann, and Justin Kirby.
- Division of Cancer Therapeutics and Diagnosis/National Cancer Institute James L. Tatum, MD, Paula M Jacobs, PhD, Melinda G. Hollingshead, DVM, and James H. Doroshow, MD
- PixelMed Publishing Special Thanks to David A. Clunie, MD
- University of Arkansas for Medical Sciences Special Thanks to Kirk E. Smith
- This project has been funded in whole or in part with Federal funds from the National Cancer Institution,
   National Institutes of Health, under Contract Number HHSN261200800001E. The content of this publication
   does not necessarily reflect the views or policies of the Department of Health and Human Services, nor does
   mention of trade names, commercial products, or organizations imply endorsement by the U.S. Government.

#### **Data Access**

#### **Data Access**

Data Type	Download all or Query/Filter	License
-----------	---------------------------------	---------

Images (DICOM, 2.8 GB)	Download Search (Download requires NBIA Data Retriever)	CC BY 4.0
Standard Operating Procedure 50101: MRI T2 Weighted Non-Contrast Protocol: Single Mouse Pulmonary Gated and Multi-Mouse Non-Gated (pdf, 141 kB)	Download	CC BY 4.0
Standard Operating Procedure 50102: Positron Emission Tomography (PET) imaging protocol (pdf, 165 kB)	Download	CC BY 4.0

Click the Versions tab for more info about data releases.

#### **Additional Resources for this Dataset**

The National Cancer Institute (NCI) has developed a national repository of Patient-Derived Models (PDMs) comprised of patient-derived xenografts (PDXs), in vitro patient-derived tumor cell cultures (PDCs) and cancer associated fibroblasts (CAFs) as well as patient-derived organoids (PDOrg). These models serve as a resource for public-private partnerships and for academic drug discovery efforts. These PDMs are clinically-annotated with molecular information and made available in the Patient-Derived Model Repository. Data related to the specific subjects in this Collection can be found at:

PDMR-521955-158-R4

The NCI Cancer Research Data Commons (CRDC) provides access to additional data and a cloud-based data science infrastructure that connects data sets with analytics tools to allow users to share, integrate, analyze, and visualize cancer research data.

• Imaging Data Commons (IDC) (Imaging Data)

#### **Detailed Description**

#### **Detailed Description**

Image Statistics	Radiology Image Statistics
Modalities	MR,SR
Number of Patients	20
Number of Studies	142
Number of Series	264
Number of Images	4608
Images Size (GB)	2.8

<u>Citations & Data Usage Policy</u>
Citations & Data Usage Policy

Users must abide by the TCIA Data Usage Policy and Restrictions. Attribution should include references to the following citations:



#### (i) Data Citation

Tatum, J., Kalen, J., Jacobs, P., Ileva, lilia, Riffle, L., Keita, S., Patel, N., Sanders, C., James, A., Difilippantonio, S., Thang, L., Hollingshead, M., Evrard, Y., Edmondson, E., Clunie, D., Liu, Y., Suloway, C., Smith, K., Wagner, U., Freymann, J. B., Kirby, J., Doroshow, J. (2022). Imaging characterization of a metastatic patient derived model of adenocarcinoma pancreas: (PDMR-521955-158-R4) (Version 1) [Data set]. The Cancer Imaging Archive. https://doi.org/10.7937/q37d-vh79



#### (i) TCIA Citation

Clark K, Vendt B, Smith K, Freymann J, Kirby J, Koppel P, Moore S, Phillips S, Maffitt D, Pringle M, Tarbox L, Prior F. The Cancer Imaging Archive (TCIA): Maintaining and Operating a Public Information Repository, Journal of Digital Imaging, Volume 26, Number 6, December, 2013, pp 1045-1057. DOI: 10.1007 /s10278-013-9622-7

#### Other Publications Using This Data

TCIA maintains a list of publications which leverage TCIA data. If you have a manuscript you'd like to add please contact the TCIA Helpdesk.

#### **Versions**

#### Version 1 (Current): Updated 2022/08/17

Data Type	Download all or Query/Filter
Image (DICOM, 2.8 GB)	Download Search (Download requires the NBIA Data Retriever)
Standard Operating Procedure 50101: MRI T2 Weighted Non-Contrast Protocol: Single Mouse Pulmonary Gated and Multi-Mouse Non-Gated	Download
Standard Operating Procedure 50102: Positron Emission Tomography (PET) imaging protocol	Download